Thrombin-Jmi, Thrombocoll Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to growth in surgical procedure volumes, wider availability of human thrombin products, increasing adoption of advanced wound care materials, expansion of hospital surgical infrastructure, improved clinician familiarity with hemostatic agents.

The growth in the forecast period can be attributed to increasing demand for efficient intraoperative bleeding management, expansion of trauma and emergency care services, rising use of biologic hemostats in complex surgeries, ongoing innovation in surgical sealants, growing investments in advanced surgical products. Major trends in the forecast period include increasing use of topical hemostatic agents in surgery, rising demand for rapid bleeding control solutions, expansion of minimally invasive surgical procedures, growing adoption of collagen-based hemostats, enhanced focus on surgical safety and outcomes.

The rising incidence of bleeding disorders is expected to drive the growth of the thrombin-JMI and thrombocoll market in the coming years. Bleeding disorders are conditions characterized by abnormal or excessive blood loss, whether external or internal, due to injury, medical conditions, or clotting deficiencies. The incidence of these disorders is increasing due to an aging population and the growing use of anticoagulants, both of which elevate the risk of bleeding complications. Thrombin-JMI and Thrombocoll help manage bleeding by promoting clot formation - Thrombin-JMI activates the clotting cascade, while Thrombocoll enhances platelet aggregation and fibrin formation at wound sites. For example, according to Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, in April 2025 the UK haemophilia A and B patient population exceeded 11,800 individuals during the 2023/24 period, highlighting a sizable and clinically significant treated population. Therefore, the rising incidence of bleeding disorders is driving growth in the thrombin-JMI and thrombocoll market.

The rising number of surgical procedures is also expected to propel the growth of the thrombin-JMI and thrombocoll market. Surgical procedures involve medical interventions performed to treat diseases, injuries, or conditions by modifying or removing body tissues, often through incisions or other invasive techniques. The number of surgeries is increasing due to an aging population requiring more medical interventions and advances in minimally invasive techniques that improve safety and recovery times. Thrombin-JMI and Thrombocoll serve as hemostatic agents in surgeries, with Thrombin-JMI activating fibrinogen for clot formation and Thrombocoll providing a collagen scaffold to stimulate platelet aggregation. For example, according to the American Society of Plastic Surgeons, a US-based non-profit organization, minimally invasive procedures increased by 7% in 2023, outpacing the growth of traditional surgeries by 2%. Hand surgeries, including carpal tunnel, arthritis, and trigger finger procedures, totaled 207,887 in 2023, a 2% increase from 2022. Therefore, the growing number of surgical procedures is driving the thrombin-JMI and thrombocoll market.

The increasing aging population is also expected to support the growth of the thrombin-JMI and thrombocoll market. An aging population refers to a demographic trend in which the proportion of elderly individuals grows due to longer life expectancy and lower birth rates. This increase is driven by healthcare advancements that extend life and declining birth rates in many regions. Thrombin-JMI and Thrombocoll help older adults by promoting blood clotting and controlling bleeding, which is especially important for those who experience slower wound healing and higher bleeding risks due to age-related conditions. For instance, according to the U.S. Census Bureau, in January 2024 the U.S. population aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, reflecting a 47% increase. The proportion of this age group within the total population is projected to rise from 17% to 23% during the same period. Consequently, the growing aging population is driving the thrombin-JMI and thrombocoll market.

Major companies operating in the thrombin-jmi, thrombocoll market are Pfizer Inc.

North America was the largest region in the thrombin-jmi, thrombocoll market in 2025. The regions covered in the thrombin-jmi, thrombocoll market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the thrombin-jmi, thrombocoll market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the thrombin-jmi and thrombocoll market by increasing costs of imported human plasma derivatives, collagen raw materials, sterile processing supplies, and specialized surgical packaging components. Hospitals and surgical centers in North America and Europe are particularly affected due to reliance on imported biologic hemostats, while Asia-Pacific faces higher manufacturing input costs. These tariffs can elevate product pricing and procurement costs for healthcare providers. At the same time, they are supporting localized production of surgical hemostatic products, regional sourcing of biomaterials, and long-term supply chain strengthening.

The thrombin-jmi, thrombocoll market research report is one of a series of new reports that provides thrombin-jmi, thrombocoll market statistics, including thrombin-jmi, thrombocoll industry global market size, regional shares, competitors with a thrombin-jmi, thrombocoll market share, detailed thrombin-jmi, thrombocoll market segments, market trends and opportunities, and any further data you may need to thrive in the thrombin-jmi, thrombocoll industry. This thrombin-jmi, thrombocoll market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Thrombin-JMI and Thrombocoll are medical products used to control bleeding during surgical procedures. Thrombin-JMI is a human thrombin-based hemostatic agent that promotes clot formation to manage bleeding during surgery. Thrombocoll is a collagen-based hemostatic product that aids in stopping bleeding by supporting platelet aggregation and clot formation during surgical procedures. Both are used in clinical settings to prevent or control excessive bleeding during surgeries or invasive procedures.

The primary indications for Thrombin-JMI and Thrombocoll are surgical procedures and trauma management. Surgical procedures are medical operations performed by trained surgeons to treat or manage diseases, injuries, or conditions using instruments, often involving incisions or alterations to the body. These products are available in solution and powder formulations and serve various end users, including hospitals, diagnostic centers, and clinics.

The thrombin-jmi, thrombocoll market consists of sales of hemostatic kits, reconstitution kits, coseal, floseal hemostatic matrix, and tachoSil. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.